Advancing medicines

Solving therapeutic problems

Improving lives

Aquestive is a specialty pharmaceutical company that advances and commercializes medicines to solve therapeutic problems and meaningfully improve people’s lives. We apply innovative drug delivery technology and scientific expertise to redesign important medicines. Our initial focus, supported by our current approved products and late-stage pipeline, is to improve medications and outcomes for patients with central nervous system (CNS) conditions.

Our success is proven

2B+

PharmFilm® doses consumed by patients

200+

Worldwide patents

Continents where our products are sold

Aquestive works hand-in-hand with our partners to address their toughest challenges—enhancing existing molecules and providing a development platform for new ones. We have comprehensive capabilities to advance medicines from pipeline to market. Partners can rely on our scientific and regulatory expertise, integrated development capabilities, and world-class clinical and commercial manufacturing operations. More than 2 billion commercial doses have been delivered with our PharmFilm® technology.

News Articles

Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020

WARREN, N.J. , Feb. 20, 2020 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that it will report

Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film

FDA Acceptance of Libervant ™ (diazepam) Buccal Film NDA for Management of Seizure Clusters Potential for First Oral Diazepam-Based Therapy for Population of 1.2 million Refractory Epilepsy Patients Assigned Prescription Drug User Fee Act (PDUFA) Goal Date of September 27, 2020 WARREN, N.J. , Feb.

Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment

Pre-IND Meeting on AQST-108 Completed FDA Confirmed AQST-108 To Be Reviewed Under 505(b)(2) No Additional Clinical Studies Would Be Required Prior to Opening Proposed IND Pivotal Pharmacokinetic (PK) Clinical Trials Planned To Be Initiated Before Year End 2020 WARREN, N.J. , Feb.

Newsroom

References

1. Bala R, Pawar P, Khanna S, Arora S. Orally dissolving strips: A new approach to oral drug delivery system. Int J Pharm Investig. 2013;3(2):67–76.

2. Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in seizure emergencies: a systematic review. Epilepsy Behav. 2016;63:109–117.

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-941-1900.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

Full name*
Email address*
Street Address*
City*
Zip Code*
Phone number*
Tell us how we can help your brand
Send me a kit
- Send me a PharmFilm® demonstration kit
I am interested in:
- Commercializing an existing product
- Commercializing a product in development
- Investment opportunities
To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive marketing updates regarding products and services from Aquestive Therapeutics.

Please complete this form:

Full name*
Email address*
Phone number*
What is your question?*
In what clinical trial are you interested?
To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

Full name*
Email address*
Phone number*
What is your question?*
To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.
Subscribe
- I would like to receive information updates regarding products and services from Aquestive, and information about Aquestive-sponsored clinical trials.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”

First Name*
Last Name*
Email Address*
Phone Number*
Role within the Epilepsy Community*
- Patient/Caregiver
- HCP
- Other
Tell us how we can assist you
- By providing my contact information, I agree that Aquestive Therapeutics (“Aquestive”) can use such information for its marketing database and that Aquestive and its agents may contact me by mail or email to provide information about Aquestive or its products or services. I understand that my contact information will not be sold to third parties, other than in the event Aquestive or its affiliates are sold. I understand that I have the right to opt-out of the database and have my information removed from the database at any time. Instructions on how to be removed from the database will be included in any future communications sent to me by Aquestive. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing lgsart@aquestive.com.

OUR QUEST

Advancing medicines
Solving therapeutic problems
Improving lives

OUR QUEST

Deliver clinical and therapeutic advances

Pipeline

Innovative Drug Delivery

Commitment to Epilepsy

Advancing medicines

Solving therapeutic problems

Improving lives

Our success is proven

PharmFilm® doses consumed by patients

Worldwide patents

Continents where our products are sold

News Articles

Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020

Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film

Aquestive Therapeutics Announces FDA Confirmed 505(b)(2) Pathway for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment

References

Please complete this form:

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

Please complete this form:

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”